IPO registrations (S-1, F-1) · Registrants
ELUTIA INC.
- SEC CIK
- 1708527 · filings on EDGAR ↗
- Name on the registration
- AZIYO BIOLOGICS, INC.
- Former names
- AZIYO BIOLOGICS, INC. (2017–2023)
- Registration
- Form S-1, first filed 2020-09-14, last 2020-09-30; 1 initial registration, 1 amendment
- Outcome
- Final prospectus filed 2020-10-08; declared effective 2020-10-07
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 12510 PROSPERITY DRIVE, SUITE 370, Silver Spring, MD 20904
- EIN
- 47-4790334
- Ticker
- ELUT (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- ELUTIA INC. on the corporate pages
Offering terms
- Proposed price range
- $16.00–$18.00 per share (S-1/A filed 2020-09-30)
- Final price
- $17.00 per share, within the range (424B4 filed 2020-10-08, an initial public offering)
- Shares sold
- 2,941,176
- Gross proceeds
- $49,999,992 before underwriting discounts and any over-allotment option
- Lead underwriters
- Piper Sandler; Cowen
- Syndicate
- Cantor Fitzgerald; Truist Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: ELUTIA INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: ELUTIA INC. Fuzzy (name and state)
- Form 5500 plan sponsor: ELUTIA INC. EXACT (EIN (EXACT))
- Federal award recipient: ELUTIA INC. Fuzzy (name and state)
- Form D issuer: ELUTIA INC. EXACT (CIK (EXACT))
- SEC filer: AZIYO BIOLOGICS, INC. EXACT (CIK (EXACT))
- Person page: Guido J Neels Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-09-14 | S-1 | S-1 (registration) | AZIYO BIOLOGICS, INC. | 0001104659-20-104884 ↗ |
| 2020-09-30 | S-1/A | S-1/A (amendment) | AZIYO BIOLOGICS, INC. | 0001104659-20-110107 ↗ |
| 2020-10-07 | EFFECT | EFFECT (declared effective) | AZIYO BIOLOGICS, INC. | 9999999995-20-002773 ↗ |
| 2020-10-08 | 424B4 | 424B4 (final prospectus) | AZIYO BIOLOGICS, INC. | 0001104659-20-113469 ↗ |
| 2022-02-03 | EFFECT | EFFECT (declared effective) | AZIYO BIOLOGICS, INC. | 9999999995-22-000332 ↗ |
| 2022-09-08 | EFFECT | EFFECT (declared effective) | AZIYO BIOLOGICS, INC. | 9999999995-22-002636 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-09-30 | S-1/A | registration statement | $16.00–$18.00 | 2,941,176 | - | 4 | primary document; range, shares headline, cover names 4 | document ↗ | ||
| 2020-10-08 | 424B4 | final prospectus | $17.00 | 2,941,176 | $49,999,992 | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| CORMATRIX CARDIOVASCULAR INC | TenPercentOwner | 1 | 2020 | ||
| Englese Thomas | Officer | Chief Commercial Officer; CHIEF COMMERCIAL OFFICER | 7 | 2020–2023 | |
| Ferguson Matthew | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 26 | 2020–2026 | |
| HighCape Capital, LLC | Director,TenPercentOwner; TenPercentOwner | 12 | 2020–2025 | ||
| HighCape Capital, L.P. | Director,TenPercentOwner; TenPercentOwner | 13 | 2020–2025 | ||
| HighCape Co-Investment Vehicle II, LLC | Director,TenPercentOwner; TenPercentOwner | 13 | 2020–2025 | ||
| HighCape Co-Investment Vehicle I, LLC | Director,TenPercentOwner; TenPercentOwner | 13 | 2020–2025 | ||
| HighCape Partners GP, LLC | Director,TenPercentOwner; TenPercentOwner | 13 | 2020–2025 | ||
| HighCape Partners GP, L.P. | Director,TenPercentOwner; TenPercentOwner | 13 | 2020–2025 | ||
| HIGHCAPE PARTNERS, L.P. | Director,TenPercentOwner; TenPercentOwner | 13 | 2020–2025 | ||
| HIGHCAPE PARTNERS QP, L.P. | Director,TenPercentOwner; TenPercentOwner | 13 | 2020–2025 | ||
| Jordan Maybelle | Director | 7 | 2020–2025 | ||
| Keralink International, Inc. | TenPercentOwner | 1 | 2020 | ||
| LLOYD RONALD K. | Director,Officer | President and CEO; PRESIDENT AND CEO | 6 | 2020–2022 | |
| Makes Brigid | Director | 10 | 2020–2026 | ||
| Mills C Randal | Director; Director,Officer | Interim President and CEO; PRESIDENT AND CEO | 26 | 2020–2026 | |
| RAKIN KEVIN | Director,TenPercentOwner | 21 | 2020–2026 | ||
| Riebman Jerome | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 5 | 2020–2022 | |
| Roberts Darryl | Officer | EVP and General Manager, Muscu; EVP, OPERATIONS & PRODUCT DEV.; EVP, Operations & Product Deve | 4 | 2020–2022 | |
| Zuga Matt | Director,TenPercentOwner | 14 | 2020–2025 | ||
| Edwards Peter G | Officer | GENERAL COUNSEL | 4 | 2021–2022 | |
| Williams Michelle LeRoux | Officer | Chief Scientific Officer; CHIEF SCIENTIFIC OFFICER | 15 | 2022–2026 | |
| Colpman David | Director | 9 | 2022–2026 | ||
| HighCape Partners GP II, LLC | TenPercentOwner | 9 | 2022–2026 | ||
| HighCape Partners GP II, L.P. | TenPercentOwner | 10 | 2022–2026 | ||
| HighCape Partners II, L.P. | TenPercentOwner | 5 | 2022–2024 | ||
| HighCape Partners QP II, L.P. | TenPercentOwner | 9 | 2022–2026 | ||
| Birchview Capital, LP | Other; TenPercentOwner | 5 | 2023–2024 | ||
| Birchview Fund LLC | Other; TenPercentOwner | 5 | 2023–2024 | ||
| Strobeck Matthew | Other; TenPercentOwner | 5 | 2023–2024 | ||
| Elutia PIPE Investment, LP | TenPercentOwner | 1 | 2023 | ||
| NEELS GUIDO J | Director | 7 | 2025–2026 | person page Fuzzy |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2023-10-03 | ELUTIA INC. | Biotechnology | $10,500,000 | $10,500,000 | 12 | 1 |
| 2021-12-22 | AZIYO BIOLOGICS, INC. | Biotechnology | $13,999,975 | $13,999,975 | 15 | 1 |
| 2020-09-14 | AZIYO BIOLOGICS, INC. | Biotechnology | $5,039,427 | $5,039,427 | 5 | 1 |
| 2019-12-18 | AZIYO BIOLOGICS, INC. | Biotechnology | $3,500,000 | $3,050,230 | 5 | 1 |
| 2018-08-06 | AZIYO BIOLOGICS, INC. | Biotechnology | $10,000,000 | $10,000,000 | 7 | 1 |
| 2017-06-09 | AZIYO BIOLOGICS, INC. | Biotechnology | $12,000,000 | $12,000,000 | 3 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | ELUTIA INC. | MD | State business registries | EIN (EXACT, as the state registration reports it) |
| Form D issuer | ELUTIA INC. | MD | Form D private offerings | CIK (EXACT) |
| SEC filer | ELUTIA INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | ELUTIA INC. | State business registries | name and state | |
| Form 5500 plan sponsor | ELUTIA INC. | EIN (EXACT) | ||
| Federal award recipient | ELUTIA INC. | Federal spending (USAspending) | name and state | |
| Person page | Guido J Neels | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), MD first:
- MICROMET, INC. MD
- OSIRIS THERAPEUTICS, INC. MD
- REGENXBIO Inc. MD
- CHAMPIONS ONCOLOGY, INC. MD
- CASI Pharmaceuticals, Inc (DE) MD
- BioNTech SE 2M
- Immatics N.V. 2M
- CHEMOKINE THERAPEUTICS CORP A1
- Fusion Pharmaceuticals Inc. A6
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. AZ
In other datasets, the same topic (Health) in MD:
- Nonprofit: 4K FOR CANCER INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health